Promising therapeutic options in triple-negative breast cancer

被引:0
作者
Bilici, A. [2 ]
Arslan, C. [1 ]
Altundag, K. [1 ]
机构
[1] Hacettepe Univ, Dept Med Oncol, Inst Oncol, Ankara, Turkey
[2] Sisli Etfal Res & Training Hosp, Dept Med Oncol, Istanbul, Turkey
来源
JOURNAL OF BUON | 2012年 / 17卷 / 02期
关键词
basal-like; breast cancer; treatment; triple negative; PATHOLOGICAL COMPLETE RESPONSE; PACLITAXEL PLUS BEVACIZUMAB; TYROSINE KINASE INHIBITOR; RANDOMIZED PHASE-II; BASAL-LIKE SUBTYPE; POLY(ADP-RIBOSE) POLYMERASE; NEOADJUVANT CHEMOTHERAPY; INFUSIONAL FLUOROURACIL; ADJUVANT CHEMOTHERAPY; ANTITUMOR-ACTIVITY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Triple-negative breast cancer (TNBC) has a greater risk of recurrence despite more aggressive therapy even in low-risk category. TNBC is high grade, hormone receptor and HER-2 negative, it exhibits a high level of Ki-67 staining and expresses the epithelial growth factor receptor (EGFR). Because of its expression profile, treatment options are limited to cytotoxic chemotherapy. Molecular defects that give rise to BRCA1-associated breast cancer also occur in TNBC. Thus, the combination of poly-(ADP-ribose)-polymerase (PARP) inhibitors with drugs that cause DNA breakages, such as alkylating agents and topoisomerase I inhibitors, could theoretically potentiate the efficacy of each drug in patients with TNBC. Clinical trials with various targeted approaches alone or in combination with different chemotherapeutic agents are currently underway. In this review, current and future treatment approaches in TNBC with novel targeted agents are discussed.
引用
收藏
页码:209 / 222
页数:14
相关论文
共 50 条
  • [31] Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
    Le Du, Fanny
    Eckhardt, Bedrich L.
    Lim, Bora
    Litton, Jennifer K.
    Moulder, Stacy
    Meric-Bernstam, Funda
    Gonzalez-Angulo, Ana M.
    Ueno, Naoto T.
    [J]. ONCOTARGET, 2015, 6 (15) : 12890 - 12908
  • [32] Neoadjuvant chemotherapy in HER2-positive and triple-negative breast cancer
    Goncalves, Anthony
    [J]. BULLETIN DU CANCER, 2016, 103 (06) : S76 - S89
  • [33] Biological Subtypes of Triple-Negative Breast Cancer
    Hubalek, Michael
    Czech, Theresa
    Mueller, Hannes
    [J]. BREAST CARE, 2017, 12 (01) : 8 - 14
  • [34] Triple-Negative Breast Cancer A Short Review
    Elias, Anthony D.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (06): : 637 - 645
  • [35] Practical Approach to Triple-Negative Breast Cancer
    Gadi, Vijayakrishna K.
    Davidson, Nancy E.
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (05) : 293 - +
  • [36] New Targets for Triple-Negative Breast Cancer
    Herold, Christina I.
    Anders, Carey K.
    [J]. ONCOLOGY-NEW YORK, 2013, 27 (09): : 846 - 854
  • [37] cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
    Gaule, Patricia B.
    Crown, John
    O'Donovan, Norma
    Duffy, Michael J.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (09) : 999 - 1009
  • [38] Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
    Bianchini, Giampaolo
    Balko, Justin M.
    Mayer, Ingrid A.
    Sanders, Melinda E.
    Gianni, Luca
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (11) : 674 - 690
  • [39] Clinicopathological features and treatment strategy for triple-negative breast cancer
    Yamamoto, Yutaka
    Iwase, Hirotaka
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (04) : 341 - 351
  • [40] Controversial issues in the neoadjuvant treatment of triple-negative breast cancer
    Fitzpatrick, Amanda
    Tutt, Andrew
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11